About Us

Universal Biosensors (UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. The point-of-care diagnostic market is worth US$15 billion a year and growing.

UBI has partnered with global healthcare company Siemens Healthcare Diagnostics to develop the Xprecia Stride^TM blood coagulation analyser, launched in December 2014, to help patients taking the anticoagulant drug Warfarin manage their medication.

UBI has also developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. (a Johnson & Johnson company) under the OneTouch^® Verio^® brand. 

UBI's innovative electrochemical sensor platform is being applied to a range of other medical diagnostic applications.

The company is listed on the Australian Securities Exchange under the ticker "UBI", and operates from its manufacturing and R&D facility in Melbourne, Australia.

 

Read more about Corporate Overview & Strategy